32 Based in Boston, Stapgen is a startup company dedicated to preventing Type 2 Diabetes. As a result of the fantastic minds behind the process, it’s managed to forge a cohesive approach towards accomplishing this feat. By utilising technology, Stapgen has founded a means to both measure the Intestinal Alkaline Phosphatase level in stool, and intercept the process of pathogenesis. As such, Stapgen now stands as an exclusive entry point into distributing a method for Type 2 Diabetes testing. But what is it that truly defines Stapgen’s research as revolutionary, and what difference does it make to the field of Type 2 Diabetes prevention? Firstly, it’s important to understand the necessity of Intestinal Alkaline Phosphatase. As a rule, IAP in the gut is the single most important enzyme related to Type 2 Diabetes, and a consistent deficiency ultimately results in the development of Type 2 Diabetes after roughly five years. In response to this, Stapgen found it - not just necessary - but imperative to create a way for individuals to check their IAP levels on a regular basis. The result is what we see today – an award-winning piece of Type 2 Diabetes prevention technology with the capability to deliver on the promises that it makes. However, none of it would be possible without the genius behind these innovative developments. Said genius is, of course, Stapgen’s Chief Scientist, Dr Madhu S. Malo. With both a PhD and MBBS, Dr Madhu S. Malo was an assistant professor in Harvard Medical School, and a Postdoc in MIT. With both a PhD from Sydney University and a medical degree from Dhaka Medical College under his belt, he went on to discover the root cause of Type 2 Diabetes. Following this revelation, Dr Madhu S. Malo proceeded to further detail his findings in the hopes that it would completely revolutionise the sector. He recognised that IAPD was the leading cause of Type 2 Diabetes, increasing the risk by a whopping 14 times, and quickly published his discovery in 2022 in British Medical Journal, and American Diabetes Association. From this came the potential for change, and its existence has already drastically altered the way that Type 2 Diabetes is discussed in the present medical field. Now, Dr Madhu S. Malo is delivering his expertise as a visiting professor at BIRDEM, Dhaka, and Bangladesh, and advisor to the Diabetic Association of Bangladesh. 2022’s Most Innovative Medical Aesthetic & Plastic Surgery Clinic - London Breaking Down the Barrier Between Eastern and Western Aesthetic Treatments Jul23410 This, combined with the prowess of its Founder and CEO, Dr Biplab K. Malo, presents Stapgen as a startup that’s wholly filled with brilliance. Having graduated from the University of Pennsylvania’s School of Dental Medicine in 2000, Dr Biplab K. Malo made a name for himself as the first dentist of Bangladeshi nationality to graduate from UPSDM. Since graduating, Dr Biplab K. Malo became the successful owner of a renowned dental practise that since surpassed a decade of excellence. As brothers, Dr Biplab K. Malo and Dr Madhu S. Malo have long since started their journey of revolutionising the world in their own, unique way. Both brothers have demonstrated an overwhelming dedication to completely reconstructing the way everyone, from the individual person to world renowned doctors, approaches Type 2 Diabetes. It’s this commitment that has allowed the pair to come so far, and it’s what has established Stapgen as a startup that’s wholly focused on becoming a pivotal cornerstone of the diabetes sphere. Patients needn’t feel blindsided by the possibility of a Type 2 Diabetes diagnosis, and it’s all a result of the brothers’ tireless work to forge a means to predict and prevent drastic changes. The medical field has always had the potential to advance, but Stapgen has proven that technology can lend a huge helping hand in encouraging these world-altering changes. By leveraging the opportunities that technology has presented, it’s cultivated an effective means to prevent Type 2 Diabetes – something that will no doubt go on to reshape the medical industry in its future findings. Nowhere has such devotion been displayed as absolutely as it has through Stapgen. It’s clear that improving the lives of individuals is the defining characteristic that Stapgen adheres to. With the frequent evolution of both technology and the medical sphere, developments in a multitude of areas are almost to be expected. However, instead of simply changing in relation to the industry’s growth, Stapgen has placed itself at the forefront of innovation. It’s a startup that isn’t content with simply watching change occur, but is determined to be an active part of said change. Its research and findings concerning Type 2 Diabetes are undeniably revolutionary, and there’s no doubt that its work will continue to shape the way the sector approaches the matter for the foreseeable future. Contact Details Contact: Biplab Malo Company: Stapgen Web Address: https://stapgen.com/ For years, predicting a Type 2 Diabetes diagnosis has been near impossible. As such, it has the potential to drastically alter lives without warning. However, as it seems, there may be a way to identify and prevent Type 2 Diabetes, and it’s all a product of Stapgen’s genius. Founded as a means to resolve the ever-growing issue of unpredictable Type 2 Diabetes diagnoses, Stapgen is leveraging its tireless research to set a new standard throughout the sector. Leading Pioneers in Type 2 Diabetes Prevention Technology 2023
RkJQdWJsaXNoZXIy MTUyMDQwMA==